Navigation Links
Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
Date:2/20/2009

CTI to focus on Pixantrone and OPAXIO Approval and Commercialization

SEATTLE, Feb. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it exercised its option to sell its 50% ownership interest in the Zevalin joint venture to Spectrum Pharmaceuticals, Inc. (Spectrum) for $18 million. CTI and Spectrum established a joint venture in December 2008 to develop and commercialize Zevalin. At that time CTI contributed all of the Zevalin related assets to the joint venture and sold to Spectrum a 50% membership interest in the joint venture for $15 million, plus certain milestone payments.

The Company will focus its resources on the approval of pixantrone for relapsed aggressive non-Hodgkin's lymphoma (NHL) and OPAXIO for non-small cell lung and ovarian cancer. CTI estimates that as a result of the sale of the Zevalin interest it will reduce expenses by approximately $15 million annually from activities previously associated with Zevalin while providing CTI with non-dilutive source of operating capital.

"CTI continues to believe in the value of Zevalin as a commercially attractive product and effective form of cancer therapy; however, with the impressive clinical trial results for pixantrone and given the company's need for operating capital, we are compelled to exercise our option and focus our resources on pixantrone," noted James Bianco, MD, CEO of CTI. "CTI has been proud to have provided Zevalin to patients since we acquired it in December, 2007 and having the foresight to bring the first line consolidation for indolent NHL data to the FDA for potential label expansion in the front line consolidation setting. With the progress we made in removing many of the barriers that prevent its more widespread use, we are confident Spectrum will be able to ultimately make Zevalin a commercially attractive product."

At the closing of the sale of CTI's 50% m
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... , ROCKVILLE, Md., Nov. 30 /PRNewswire-FirstCal...ay it has completed enrollment in the Phase II cli...008/2009 recommended strains) VLP vaccine candidat...r adults). This randomized, double-blind, active-...lity and immunogenicity of two different doses (15...
(Date:11/30/2009)... , SHANGHAI, Nov. 30 /PRNewswire-Asia/ ...ceutical, biotechnology, and medical-device resear...ions in China and the United States,announced tha...Fast 50 China,2009 list for the fifth consecutive ...ompanies in China,s technology, media, and telecom...
(Date:11/27/2009)... , DURHAM, N.C., Nov. 27 C...l initiate water-soluble carbon nanotube-based can...water-soluble carbon nanotubes, which have functio...n with cancer drugs, was developed in partnership ...jugated carbon nanotubes serves as a drug delivery...
(Date:11/25/2009)... , BOSTON, Nov. 25 Biotech...virus, genomic data from the 1918 pandemic through...rent H1N1 pandemic, today issued its latest bioche...at the lethality of the H1N1 ("Swine Flu") virus h...the virus,s current outbreak in the spring of 2009...
Breaking Biology Technology:NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5
...ship Completes CTI,s Transformation to Commercial ... SEATTLE, April 24 Cell Therapeutics, Inc.,(Nasd...ilips, most recently,Vice President and General Ma... President of CTI with direct responsibilities for...ive August 1, 2008. Philips, responsibilities,will...
... April 23 Anadys Pharmaceuticals,Inc. (Nasdaq: A...arter 2008,financial results on Wednesday, April 3... Anadys will hold a conference call and webcast to...and highlights and to provide an update on,its dev...5:00 p.m. Eastern,Daylight Time. A live webcast of...
...iz., April 23 ImaRx Therapeutics,Inc. (Nasdaq: I...agreement,with Abbott Laboratories pursuant to whi...million non-recourse promissory note with Abbott i...ase. As a result, full title to,the urokinase asse...product, all regulatory and clinical documentation...
Other Biology Technology:Veteran Drug Industry Executive to Become President of CTI 2Veteran Drug Industry Executive to Become President of CTI 3Veteran Drug Industry Executive to Become President of CTI 4Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results 2ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase 2ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase 3
(Date:11/26/2009)... Whitehead researchers have developed a new type ...ific genes and proteins used by pathogens, accordi...cell cultures genes are present in two copies: one.... Gene inactivation by mutation is therefore ineff...econd copy usually remains active and takes over. ...
(Date:11/26/2009)...ococcus Aureus ) and other drug-resistant bacteria... prototype devices have been developed to offer sa...ls. , Two prototype devices have been developed:....g. hands and feet) in hospitals and public spaces...her to shoot bacteria-killing agents into infested...
(Date:11/25/2009)...tomach, may be used to boost resistance to, or slo...hool of Medicine researchers report in a study pub...cience . , Parkinson,s disease is caused by a de...idbrain known as the substantia nigra, which is re...tion of dopamine in late-stage Parkinson,s causes ...
Breaking Biology News(10 mins):Knockouts in human cells point to pathogenic targets 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Hormone ghrelin can boost resistance to Parkinson's disease 2As Greenland melts 10423 1As Greenland melts 10423 2MU research team establishes family tree for cattle other ruminants 10421 1MU research team establishes family tree for cattle other ruminants 10421 2EPA fellow studies effect of mercury in toads 10419 1EPA fellow studies effect of mercury in toads 10419 2
...hagic fever have been reported in Angola. Of these...irst 6 cases, bringing the number of affected prov...ern part of the country. , Mobile surveillance tea...rday when vehicles were attacked and damaged by lo...no surveillance teams were operational today in th...
...ns researchers report that two proteins best known...her to turn the liver into a sugar-producing facto...tion of sugar is a damaging problem in people with...rget for future drugs to fight the disease, the re...liver,s production of sugar is a back-up plan that...
...ns researchers report that two proteins best known...her to turn the liver into a sugar-producing facto...tion of sugar is a damaging problem in people with...rget for future drugs to fight the disease, the re...liver,s production of sugar is a back-up plan that...
Other Biology News:WHO suspends Marburg work, appeals for new funds 2Computational verification of protein-protein interactions by orthologous co-expression 2Computational verification of protein-protein interactions by orthologous co-expression 3Future diabetes drugs may target new protein interaction 2Future diabetes drugs may target new protein interaction 3
Custom Human Cytokine Antibody Array, Choose from hundreds of proteins. from Raybiotech, Inc.
Goat Anti-Mouse Ig + IgM Antibody, FITC Conjugated from Cayman Chemical
CopyControl Induction Solution from EPICENTRE Biotechnologies
RNase III from Ambion
Biology Products: